Table 3.
Correlation between TMB and overall survival.
| Median survival (months) | Log-rank test | |||
|---|---|---|---|---|
| TMB-high | TMB-low | HR (95% CI) | p-value | |
| All patients | 101.4 (n = 278) | 68.1 (n = 1374) | 0.82 (0.63–1.06) | 0.151 |
| APC mutation | 101.4 (n = 189) | 70.7 (n = 1049) | 0.86 (0.63–1.18) | 0.372 |
| APC wild type | 91.8 (n = 89) | 46.9 (n = 325) | 0.66 (0.43–1.03) | 0.106 |
| KRAS mutation | 101.4 (n = 126) | 59.9 (n = 594) | 0.58 (0.40–0.83) | 0.013 |
| KRAS wild type | 98.4 (n = 152) | 82.5 (n = 780) | 1.05 (0.73–1.51) | 0.797 |
| PIK3CA mutation | – (n = 123) | 64.7 (n = 251) | 0.75 (0.47–1.20) | 0.256 |
| PIK3CA wild type | 98.4 (n = 155) | 69.1 (n = 1123) | 0.84 (0.61–1.16) | 0.327 |
| TP53 mutation | 98.4 (n = 132) | 71.9 (n = 998) | 0.92 (0.66–1.28) | 0.628 |
| TP53 wild type | – (n = 146) | 63.9 (n = 376) | 0.66 (0.41–1.07) | 0.091 |
TMB, tumor mutation burden; APC, adenomatous polyposis coli; KRAS, Kirsten rat sarcoma viral oncogene homolog; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; TP53, tumor protein p53; HR, hazard ratio.